Skip to main content
Log in

Gossypetin- based therapeutics for cognitive dysfunction in chronic unpredictable stress- exposed mice

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Chronic unpredictable stress (CUS) is a promising model for induction of cognition impairment. Stress induced memory dysfunction is linked to the activation of kynurenine (KYN) pathway. This pathway indicates that, chronic stress primarily promotes the release of excessive cortisol from the adrenal gland, which tends to activate microglia and further increases kynurenine and its downstream pathway, resulting in excessive quinolinic acid (QA), which further impairs brain derived neurotrophic factor (BDNF) levels and leads to neurodegeneration. Prior studies already established anti-oxidant and anti-depressant activity of gossypetin. This research study was mainly conducted to elaborate neuroprotective activity of gossypetin against CUS-induced cognition impairment via acting on kynurenine pathway. In this study, Swiss albino mice were exposed to various stressors for five weeks and then administered with gossypetin (5, 10 and 20 mg/kg, i.p.) from the 4th to the 7th week (from day 22 to 49). Several behavioral tests were carried out between days 36 to 49 (6th and 7th week) and further corticosterone, neurotransmitters, oxidative stress, and brain-derived neurotrophic factor (BDNF) levels were measured. Results state that CUS exposed mice showed significant improvement in the behavioral pattern after gossypetin treatment. Corticosterone levels and oxidative stress was also found to be significantly decreased in gossypetin (10 and 20 mg/kg, i.p.) treated mice when compared with CUS exposed mice. Whereas, serotonin, norepinephrine and BDNF levels were also found to be increased after gossypetin treatment. Hence, gossypetin can be considered as a neuroprotective agent against cognition impairment caused by chronic unpredictable stress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data accessibility statement

I hereby certify that all material has been included in the text and is freely accessible without limitation and that we do not have any more information.

References

Download references

Acknowledgements

The authors are thankful to SVKM’s NMIMS University in India for providing the required resources to complete this study.

Author information

Authors and Affiliations

Authors

Contributions

Mrs. Nikita Patil Samant performed, analysed and wrote original draft and Dr. Girdhari Lal Gupta conceptualized, supervised and checked the research article.

Corresponding author

Correspondence to Girdhari Lal Gupta.

Ethics declarations

Ethics statement

The Institutional Animal Ethics Committee evaluated and approved all experimental methods and protocols (IAEC). Authors also implemented the 3Rs principles of replacement, reduction, and refinement in animal studies.

Competing interest

We declare that we have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samant, N.P., Gupta, G.L. Gossypetin- based therapeutics for cognitive dysfunction in chronic unpredictable stress- exposed mice. Metab Brain Dis 37, 1527–1539 (2022). https://doi.org/10.1007/s11011-022-00971-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-022-00971-0

Keywords

Navigation